Gláucia Maria Moraes de Oliveira
31831
15. Mendes M. Cardiac rehabilitation after myocardial infarction: an invaluable intervention that
is little used in Portugal. Rev Port Cardiol. 2013 ;32:201‑3.
16. Grace SL, Bennett S, Ardern CI, et al. Cardiac rehabilitation series: Canada. Prog Cardiovasc
Dis. 2014;56:530‑5.
17. Menezes AR, Lavie CJ, Milani RV, et al. Cardiac rehabilitation in the United States. Prog
Cardiovasc Dis. 2014; 56:522‑9.
18. Anchique Santos CV, Lopez‑Jimenez F, Benaim B, et al. Cardiac rehabilitation in Latin Ame-
rica. Prog Cardiovasc Dis. 2014;57:268‑75.
19. Borghi‑Silva A, Mendes RG, Trimer R, et al. Current trends in reducing cardiovascular dis-
ease risk factors from around the world: focus on cardiac rehabilitation in Brazil. Prog Car-
diovasc Dis. 2014;56:536‑42.
20. Lewin R, Doherty P. Cardiac rehabilitation and mortality reduction after myocardial
infarction: the emperor’s new clothes? Evidence in favor of cardiac rehabilitation. Heart.
2013;99:909‑11.
21. Laukkanen JA. Cardiac rehabilitation: why is it an underused therapy? Eur Heart J. 2015;
36:1500‑1.
22. de Vries H, Kemps HM, van Engen‑Verheul MM, et al. Cardiac rehabilitation and survival in
a large representative community cohort of Dutch patients. Eur Heart J. 2015;36:1519‑28.
23. Beauchamp A, Worcester M, Ng A, et al. Attendance at cardiac rehabilitation is associated
with lower all‑cause mortality after 14 years of follow‑up. Heart. 2013; 99:620‑5.
24. Brawner CA, Abdul‑Nour K, Lewis B, et al. Relationship Between Exercise Workload
During Cardiac Rehabilitation and Outcomes in Patients With Coronary Heart Disease. Am
J Cardiol. 2016;117:1236-41.
25. Zhao S, Zhao H, Wang L, et al. Education is critical for medication adherence in patients with
coronary heart disease. Acta Cardiol. 2015;70:197‑204.
26. Karmali KN, Davies P, Taylor F, et al. Promoting patient uptake and adherence in cardiac
rehabilitation. Cochrane Database Syst Rev. 2014;6:CD007131.
27. Kotseva K, Wood D, De Backer G. et al. Use and effects of cardiac rehabilitation in patients
with coronary heart disease: results from the EUROASPIRE III survey. Eur J Prev Cardiol.
2013;20:817‑26.
28. Griffo R, Ambrosetti M, Tramarin R, et al; ICAROS investigators. Effective secondary pre-
vention through cardiac rehabilitation after coronary revascularization and predictors of
poor adherence to lifestyle modification and medication. Results of the ICAROS Survey. Int
J Cardiol. 2013;167:1390‑5.
29. Ghisi GL, Britto R, Motamedi N, et al. Disease‑related knowledge in cardiac rehabilitation
enrollees: correlates and changes. Patient Educ Couns. 2015;98:533‑9.
30. Reiner Ž, De Backer G, Fras Z, et al. EUROASPIRE Investigators. Lipid lowering drug therapy
in patients with coronary heart disease from 24 European countries ‑ Findings from the
EUROASPIRE IV survey. Atherosclerosis. 2016;246:243‑50.
31. Kotseva K, Wood D, De Bacquer D, et al. EUROASPIRE Investigators. EUROASPIRE IV: A
European Society of Cardiology survey on the lifestyle, risk factor and therapeutic manage-
ment of coronary patients from 24 European countries. Eur J Prev Cardiol. 2016;23:636‑48.
